MOTS-c

At a glance

Overview

The name refers to a short open reading frame associated with mitochondrial 12S rRNA. Discovery studies investigated its role in communication between mitochondrial metabolism and cellular responses. Later work reported better physical performance in treated mice and increased endogenous MOTS-c after exercise in people. These are different types of evidence: measuring a naturally occurring response in humans is not a treatment trial. FDA’s 2026 evaluation found major gaps in human exposure, pharmacokinetics and toxicology for proposed MOTS-c products. It remains a research compound rather than an approved metabolic or anti-aging medicine.

Supporting sources [1] [2] [3]

How it works

The original research linked MOTS-c to changes in the folate cycle and purine synthesis, leading to AMPK-related metabolic signaling. Subsequent work explored nuclear gene regulation, muscle stress responses and metabolic adaptation. The precise molecular target remains incompletely defined. These pathways offer a biological hypothesis, but do not demonstrate that injected peptide reaches sustained active concentrations in human tissues or reproduces the effects of exercise.

Supporting sources [1] [2] [3]

Original metabolic experiments

The discovery study reported prevention of age-related and diet-induced insulin resistance in mice, alongside cellular metabolic work. That supports the proposed signaling role without establishing a human obesity or diabetes treatment.

Supporting sources [1]

Human observation versus mouse intervention

A later study administered MOTS-c to mice and assessed physical performance. Its human component measured endogenous peptide changes after exercise. The human observation cannot be presented as evidence that MOTS-c injections improve exercise capacity in people.

Supporting sources [2]

What FDA’s 2026 review identified

The review found no adequate human administration data to characterize safety and highlighted missing pharmacokinetic and toxicology information. Rapid degradation in experimental human blood raised an additional exposure question. Unknown safety cannot be summarized as an absence of side effects.

Supporting sources [3]

Compounding and approval are separate

MOTS-c was discussed in the 2026 compounding advisory process. That process does not establish FDA approval of a medicine, an effective indication or a validated long-term regimen.

Supporting sources [3]

Is this an exercise replacement?

The evidence does not show that administering MOTS-c reproduces the broad effects of human physical activity. A pathway shared with exercise is a research lead, not proof that one peptide can replace training, nutrition or management of diagnosed metabolic disease.

Supporting sources [1] [2]

Common questions

Does exercise research prove that injecting MOTS-c improves human fitness? No. The cited work includes measurements of natural peptide responses in humans and administration experiments in mice; these are different types of evidence.

Does naturally occurring mean a marketed injectable is safe? No. Exogenous exposure, product identity, impurities, degradation and immune responses require direct assessment, and FDA identified substantial gaps in human safety information.

Supporting sources [1] [2] [3]